Cielo, the world's leading Recruitment Process Outsourcing (RPO) provider, has renewed its partnership with Sanofi, a global biopharmaceutical company, to help them hire the best talent in Asia.
More info..

Sanofi delivered strong Q1 2019 business EPS growth of 9.4% at CER.
More info..

Sanofi announced the 2018 fourth-quarter and full-year results.
More info..

Sanofi Delivers 2017 Business EPS in line with Guidance
More info..

Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Bioverativ Boards of Directors.
More info..

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Court of Appeals for the Federal Circuit has ordered a new trial and vacated the permanent injunction in the dispute concerning Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). This ruling means that Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent(R) (alirocumab) injection in the U.S.
More info..

A*STAR's Singapore Immunology Network (SIgN) signed a three-year partnership with the National University of Singapore (NUS), National University Hospital (NUH) and Sanofi Pasteur to embark on a Phase IV clinical trial to understand age-related loss of immunity, known as immunosenescence, in elderly.
More info..